Zymeworks Inc. (ZYME) Dividend History

Company News

• Zymeworks Announces NMPA Approval of Zanidatamab in China for Adults with Previously Treated, Unresectable or Metastatic HER2-high expression (IHC3+) Biliary Tract Cancer

  Zymeworks' zanidatamab, a dual HER2-targeted bispecific antibody, has received conditional approval from China's NMPA for the treatment of previously treated, unresectable or metastatic HER2-positive biliary tract cancer. This milestone affirms zanidatamab's clinical potential and Zymeworks' commitment to developing innovative therapies for difficult-to-treat diseases.

  GlobeNewswire Inc.

  Featured Companies: JAZZ
• Zymeworks Announces Presentations Highlighting Breadth of Oncology Portfolio at Upcoming Medical Conferences

  Zymeworks announced multiple presentations at upcoming medical conferences, including data on its oncology programs and pipeline candidates ZW171 and ZW191. The presentations highlight the company's expertise in developing novel bispecific and multispecific antibodies to address difficult-to-treat cancers.

  GlobeNewswire Inc.
• Zymeworks Announces Participation in Upcoming Investor Conferences

  Zymeworks, a clinical-stage biotechnology company, announced that it will participate in upcoming investor conferences and provided a corporate update, including presenting preclinical data on its development candidate ZW1528 for autoimmune and inflammatory diseases.

  GlobeNewswire Inc.
• Zymeworks to Report First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025

  Zymeworks, a clinical-stage biotechnology company, announced that it will report its Q1 2025 financial results and host a conference call on May 8, 2025. The company also provided updates on its pipeline, including the FDA approval of its HER2-targeted bispecific antibody Ziihera® for second-line biliary tract cancer.

  GlobeNewswire Inc.

  Featured Companies: JAZZ
• Zymeworks Announces Achievement of $14 Million Milestone from GSK Collaboration

  Zymeworks Inc. announced a $14 million cash research milestone from GSK associated with a clinical milestone. The companies have a collaboration agreement to research, develop and commercialize bispecific antibodies using Zymeworks' Azymetric platform.

  GlobeNewswire Inc.